Comprehensive in Vitro and in Vivo Analysis of Phosphatidylinositol-3-Kinase Delta (PI3Kδ) Inhibition Using GS-1101 (CAL-101) in Combination with Mammalian Target of Rapamycin (mTOR) Inhibition Using Temsirolimus or Everolimus in Mantle Cell Lymphoma (MCL)

被引：0
|
作者：
Barr, Paul M. [1 ]
Hernandez-Ilizaliturri, Francisco J. [2 ,3 ]
Murante, Thomas [1 ]
Hilchey, Shannon P. [1 ]
Peterson, Derick R. [1 ]
Kelly, Jennifer L. [1 ]
Johnson, Dave M. [4 ]
Lannutti, Brian J. [4 ]
Czuczman, Myron S. [2 ,3 ]
Friedberg, Jonathan W. [1 ]
Bernstein, Steven H. [1 ]
机构：
[1] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA
[2] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA
[3] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA
[4] Gilead Sci Inc, Seattle, WA USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3719.3719
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3719
引用
收藏
页数：2
相关论文
共 18 条
  • [1] CAL-101 (GS-1101), a Specific Inhibitor of Phosphatidylinositol-3-Kinase-Delta (PI3Kδ), Disrupts Signals From the Microenvironment, Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL)
    Meadws, Sarah A.
    Kashishian, Adam
    Johnson, David
    Ulrich, Roger G.
    Miller, Langdon L.
    Lannutti, Brian J.
    BLOOD, 2011, 118 (21) : 1593 - 1593
  • [2] The PI3K Inhibitor GS-1101 (CAL-101) Synergistically Potentiates HDAC-Induced Proliferation Inhibition and Apoptosis Through the Activation of JNK in Lymphoma Cells
    Bodo, Juraj
    Hill, Brian T.
    Zhao, Xiaoxian
    Portell, Craig A.
    Lannutti, Brian J.
    Hsi, Eric D.
    BLOOD, 2012, 120 (21)
  • [3] A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL)
    de Vos, Sven
    Schreeder, Marshall T.
    Flinn, Ian W.
    Coutre, Steven E.
    Leonard, John P.
    Wagner-Johnston, Nina D.
    Fowler, Nathan H.
    Boccia, Ralph V.
    Barrientos, Jaqueline C.
    Boyd, Thomas
    Sharman, Jeff
    Holes, Leanne
    Lannutti, Brian
    Johnson, Dave M.
    Jahn, Thomas M.
    Miller, Langdon L.
    BLOOD, 2011, 118 (21) : 1160 - 1160
  • [4] Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors
    Wanigasooriya, Kasun
    Tyler, Robert
    Barros-Silva, Joao D.
    Sinha, Yashashwi
    Ismail, Tariq
    Beggs, Andrew D.
    CANCERS, 2020, 12 (05)
  • [5] A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Sharman, Jeff
    de Vos, Sven
    Leonard, John P.
    Furman, Richard R.
    Coutre, Steven E.
    Flinn, Ian W.
    Schreeder, Marshall T.
    Barrientos, Jaqueline C.
    Wagner-Johnston, Nina D.
    Boyd, Thomas
    Fowler, Nathan H.
    Holes, Leanne
    Lannutti, Brian
    Johnson, David
    Jahn, Thomas M.
    Miller, Langdon L.
    BLOOD, 2011, 118 (21) : 779 - 780
  • [6] A phase I/II study of the selective phosphatidylinositol 3-kinase -delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL)
    Furman, Richard R.
    Barrientos, Jacqueline Claudia
    Sharman, Jeff Porter
    De Vos, Sven
    Leonard, John
    Coutre, Steven E.
    Schreeder, Marshall T.
    Wagner-Johnston, Nina D.
    Boyd, Thomas E.
    Fowler, Nathan Hale
    Flinn, Ian W.
    Boccia, Ralph V.
    Holes, Leanne
    Lannutti, Brian Joseph
    Johnson, Dave
    Jahn, Thomas Michael
    Miller, Langdon L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL)
    Wagner-Johnston, Nina D.
    De Vos, Sven
    Leonard, John
    Sharman, Jeff Porter
    Schreeder, Marshall T.
    Boccia, Ralph V.
    Barrientos, Jacqueline Claudia
    Coutre, Steven E.
    Flinn, Ian
    Boyd, Thomas E.
    Holes, Leanne
    Johnson, David Michael
    Kim, Yeonhee
    Dansey, Roger D.
    Godfrey, Wayne R.
    Fowler, Nathan Hale
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study
    Fowler, Nathan H.
    de Vos, Sven
    Schreeder, Marshall T.
    Leonard, John P.
    Flinn, Ian W.
    Coutre, Steve
    Wagner-Johnston, Nina D.
    Sharman, Jeff
    Boccia, Ralph V.
    Barrientos, Jacqueline C.
    Boyd, Thomas E.
    Holes, Leanne M.
    Lannutti, Brian J.
    Johnson, David
    Jahn, Thomas M.
    Miller, Langdon L.
    Godfrey, Wayne R.
    BLOOD, 2012, 120 (21)
  • [9] CAL-101, A SPECIFIC INHIBITOR OF PHOSPHATIDYLINOSITOL-3-KINASE-DELTA (PI3KD), ATTENUATES PATHWAY SIGNALING, INDUCES APOPTOSIS, AND ENHANCES THE ANTITUMOR ACTIVITY OF THE MTOR INHIBITOR, EVEROLIMUS (RAD001), IN MANTLE CELL LYMPHOMA (MCL)
    Meadows, S. A.
    Kashishian, A.
    Miller, L. L.
    Lannutti, B. J.
    ANNALS OF ONCOLOGY, 2011, 22 : 199 - 199
  • [10] UGT-catalyzed glucuronidation: An important elimination mechanism of GS-1101 (CAL-101), a potent and selective inhibitor of the P110 delta isoform of phosphoinositide 3-kinase (PI3K delta) for treatment of patients with hematologic malignancies
    Chen, Hao
    Webb, Heather
    Evarts, Jerry
    Ulrich, Roger
    DRUG METABOLISM REVIEWS, 2011, 43 : 79 - 80
12